Stock comparison
Halozyme Therapeutics
Haleon
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
HALO
Halozyme Therapeutics
Market cap
$8.1B
Sector
Healthcare
HLN
Haleon
Market cap
$41.25B
Sector
Healthcare
Overall winner
Halozyme Therapeutics HALO
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | HALO | HLN | Winner |
|---|---|---|---|
| Warren Buffett | 79B | 54D | HALO |
| Benjamin Graham | 83A | 55C | HALO |
| Philip Fisher | 65B | 49D | HALO |
| Peter Lynch | 53D | 54C | HLN |
| Joel Greenblatt | 40D | 49D | HLN |
| Charlie Munger | 80C | 47D | HALO |
| Terry Smith | 84A | 43D | HALO |
Side-by-side metrics
| Metric | HALO | HLN |
|---|---|---|
| Market cap | $8.1B | $41.25B |
| P/E (TTM) | 24.0x | 28.8x |
| EV/EBIT | 10.2x | 35.6x |
| ROIC (TTM) | 23.65% | 4.13% |
| Gross margin | 81.24% | 61.45% |
| Net margin | 23.13% | 12.59% |
| Revenue CAGR 5y | 33.23% | 3.11% |
| EPS CAGR 5y | -1.98% | 4.66% |
| Debt / Equity | 1.0x | 0.5x |
| Dividend yield | 0.0% | 2.15% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
HALO leads on
- Revenue CAGR 5y33.23%vs 3.11%+91%
- ROIC (TTM)23.65%vs 4.13%+83%
- EV/EBIT10.2xvs 35.6x+71%
- Net margin23.13%vs 12.59%+46%
HLN leads on
- EPS CAGR 5y4.66%vs -1.98%+142%
- Dividend yield2.15%vs 0.0%+100%
- Market cap$41.25Bvs $8.1B+80%
- Debt / Equity0.5xvs 1.0x+45%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.